Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

Investing.com -- Morgan Stanley has released its latest rankings of small and mid-cap biotech companies, highlighting firms ...

In this article, we will take a look at 9 Oversold Biotech Stocks to Invest In. Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value ...

Nektar Therapeutics today announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in ...

In this piece, we discuss the 10 Best Small-Cap Biotech Stocks to Buy According to Analysts. Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention. This ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...